
    
      Subjects will be stratified by sex and then randomly assigned to active progesterone (PRO) or
      placebo (PBO).

      Telephone screening and visit invitation leads to the consent process and in-person screening
      including medical-psychiatric evaluation for inclusion/exclusion, then randomization and
      medication induction, stable medication with medication reduction and final evaluation for
      secondary outcomes.
    
  